1. Home
  2. FLYW vs AGIO Comparison

FLYW vs AGIO Comparison

Compare FLYW & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

N/A

Current Price

$12.53

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$29.95

Market Cap

1.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FLYW
AGIO
Founded
2009
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
FLYW
AGIO
Price
$12.53
$29.95
Analyst Decision
Buy
Buy
Analyst Count
15
8
Target Price
$15.47
$36.63
AVG Volume (30 Days)
1.7M
790.9K
Earning Date
05-27-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
N/A
EPS
0.11
N/A
Revenue
$623,025,000.00
$43,011,000.00
Revenue This Year
$14.26
$103.08
Revenue Next Year
$15.75
$126.67
P/E Ratio
$113.82
N/A
Revenue Growth
26.59
N/A
52 Week Low
$8.20
$22.24
52 Week High
$15.25
$46.00

Technical Indicators

Market Signals
Indicator
FLYW
AGIO
Relative Strength Index (RSI) 55.83 57.43
Support Level $12.47 $26.40
Resistance Level $13.18 $29.49
Average True Range (ATR) 0.52 1.09
MACD 0.23 0.27
Stochastic Oscillator 94.17 69.55

Price Performance

Historical Comparison
FLYW
AGIO

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements namely a payments platform; a proprietary payment network and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: